Header Logo

Connection

PADMANEE SHARMA to Pyridones

Back to Details
This is a "connection" page, showing publications PADMANEE SHARMA has written about Pyridones.
PADMANEE SHARMA
Connection Strength
0.125
Pyridones
  1. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.125
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.